The Impella 2.5 L for percutaneous mechanical circulatory support in severe humoral allograft rejection

Journal of Invasive Cardiology

Volumn 22, Issue 3, 2010, Pages

  Beyer, Anna T ^a   Hui, Peter Y ^a   Hauesslein, Ernest ^a  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DIURETIC AGENT; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; PREDNISONE; RITUXIMAB;

ACUTE GRAFT REJECTION; ADULT; AORTA BALLOON; ARTICLE; BRADYCARDIA; CARDIAC GRAFT REJECTION; CARDIOGENIC SHOCK; CASE REPORT; DISEASE SEVERITY; DYSPNEA; HEART ASSIST DEVICE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; HUMORAL IMMUNITY; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; MALE; PLASMAPHERESIS; PULMONARY HYPERTENSION; RESUSCITATION;

BIOPSY; GRAFT REJECTION; HEART TRANSPLANTATION; HEART-ASSIST DEVICES; HUMANS; IMMUNITY, HUMORAL; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIUM; PLASMAPHERESIS; SHOCK, CARDIOGENIC; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77749286165     PISSN: 10423931     EISSN: 15572501     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: Risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003;22:58-69.
2. Almuti K, Haythe J, Dwyer E, et al. The changing pattern of humoral rejection in cardiac transplant recipients. Transplantation 2007;84:498-503.
3. Grauhan O, Knosalla C, Ewert R, et al. Plasmapheresis and cyclophosphamide in the treatment of humoral rejection after heart transplantation. J Heart Lung Transplant 2001;20:316-321.
4. Meyns B, Dens J, Sergeant P, et al. Initial experiences with the Impella device in patients with cardiogenic shock - Impella support for cardiogenic shock. Thorac Cardiovasc Surg 2003;51:312-317.
5. Remmelink M, Sjauw KD, Henriques JP, et al. Effects of left ventricular unloading by Impella Recover LP2.5 on coronary hemodynamics. Catheter Cardiovasc Interv 2007;70:532-537.
6. Seyfarth M, Sibbing D, Bauer I, et al. A randomized clinical trial to evaluate the safety and efficacy of a percutaneous left ventricular assist device versus intra-aortic balloon pumping for treatment of cardiogenic shock caused by myocardial infarction. J Am Coll Cardiol 2008 52:1584-1588.
7. Bautista-Hernández V, Gutiérrez F, Pinar E, et al. Initial experience with the Impella left ventricular assist device for postcardiotomy cardiogenic shock and unprotected left coronary artery angioplasty in patients with a low left ventricular ejection fraction. Rev Esp Cardiol 2007;60:984-987.
8. Ramondo A, Napodano M, Tarantini G, et al. High-risk percutaneous coronary intervention using the intracardiac microaxial pump "Impella Recover". J Cardiovasc Med (Hagerstown) 2006;7:149-152.
9. Henriques J, Remmelink, M, Baan, J, et al. Safety and feasibility of elective highrisk percutaneous coronary intervention procedures with left ventricular support of the Impella Recover LP 2.5. Am J Cardiol 2006;97:990-992.
10. Taylor DO, Yowell RL, Kfoury AG, et al. Allograft coronary artery disease: Clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000;19:518-521.
11. Christoph A, Prondzinsky R, Russ M, et al. Early and sustained hemodynamic improvement with levosimendan compared to intraaortic balloon counterpulsation (IABP) in cardiogenic shock complicating acute myocardial infarction. Acute Cardiac Care 2008;10:49-57
12. Thiele H, Sick P, Boudriot E, et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Euro Heart J 2005:26;1276-1283.
13. Burkhoff D, Cohen H, Brunckhorst C, et al. A randomized multicenter clinical study to evaluate the safety and efficacy of the TandemHeart percutaneous ventricular assist device versus conventional therapy with intraaortic balloon pumping for treatment of cardiogenic shock. Am Heart J 2006;152:469.e1-469.e8